# Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

> **NCT01211457** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Cyclacel Pharmaceuticals, Inc.** · enrollment: 65 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** sapacitabine and decitabine (Part 1 - completed)
- **DRUG:** sapacitabine and venetoclax (Part 2 - recruiting)

## Key facts

- **NCT ID:** NCT01211457
- **Lead sponsor:** Cyclacel Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-06-17
- **Primary completion:** 2020-06-20
- **Final completion:** 2020-12-31
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2019-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01211457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01211457, "Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01211457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*